The effect of pioglitazone on hepatic glucose uptake measured with indirect and direct methods in alloxan-induced diabetic dogs

Diabetes

Volumn 46, Issue 2, 1997, Pages 224-231

  Matsuhisa, Munehide ^a,c   Shi, Z Qing ^a   Wan, Calvin ^a   Lekas, Michael ^a   Rodgers, Carol D ^b   Giacca, Adria ^a   Kawamori, Ryuzo ^d   Vranic, Mladen ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^d JUNTENDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; FATTY ACID; GLUCAGON; GLUCOSE; INSULIN; LACTIC ACID; PIOGLITAZONE;

ALLOXAN DIABETES MELLITUS; ANIMAL MODEL; ARTERIAL PRESSURE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DOG; DRUG MECHANISM; FATTY ACID BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE INFUSION; GLUCOSE TRANSPORT; GLUCOSE UTILIZATION; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; LIVER BLOOD FLOW; LIVER METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL;

EID: 0030904142     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diab.46.2.224     Document Type: Article

References (41)

1. Revers RR, Fink R, Griffin H, Olefsky JM, Kolterman OG: Influence of hyperglycemia on insulin's in vivo effects in type II diabetes. J Clin Invest 73:664-672, 1984
2. Yki-Jarvinen H, Helve E, Koivisto VA: Hyperglycemia decreases glucose uptake in type I diabetes. Diabetes 36:892-889, 1987
3. Vuorinen-Markkola H, Koivisto VA, Yki-Jarvinen H: Mechanism of hyperglycemia-induced insulin resistance in whole body and skeletal muscle of type I diabetic patients. Diabetes 41:571-580, 1992
4. Garvey WT, Olefsky JM, Griffin J, Hamman RF, Kolterman OG: The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes 34:222-234, 1985
5. Yki-Jarvinen H, Koivisto VA: Natural course of insulin resistance in type I diabetes. N Engl J Med 315:224-230, 1986
6. Firth RG, Bell PM, Rizza RA: Effects of tolazamide and exogenous insulin on insulin action in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 314:1280-1286, 1986
7. Rossetti L, Smith D, Shuman GI, Papachristou D, DeFronzo RA: Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 79:1510-1515, 1987
8. Lisato G, Cusin I, Tiengo A, Del Prato S, Jeanrenaud B: The contribution of hyperglycemia and hypoinsulinemia to the insulin resistance of streptozotocin-diabetic rats. Diabetologia 35:310-315, 1992
9. DeFronzo RA, Simonson D, Ferrannini E: Hepatic and peripheral insulin resistance: a common feature of type 2 (non-insulin-dependent) and type 1 (insulin-dependent) diabetes mellitus. Diabetologia 23:313-319, 1982
10. Kawamori R, Kubota MI, Ikeda M, Matsuhisa M, Kubota MA, Morishima T, Kamada T: Quantitative determination of hepatic glucose uptake using an innovative approach: effect of strict glycemic regulation and exercise in diabetic subjects. J Nutr Sci Vitaminol 37:S35-S42, 1991
11. Sakura H, Kawamori R, Kubota M, Morishima T, Kamada T, Akanuma Y, Yazaki Y, Kadowaki T: Glucokinase gene mutation and impaired glucose uptake by liver. Lancet 341:1532-1533, 1993
12. Sugiyama Y, Taketomi S, Shimura Y, Ikeda H, Fujita T: Effects of pioglitazone on glucose and lipid metabolism in Wistar fatty rats. Arzneimittelforschung 40:263-267, 1990
13. Hofmann A, Lorenz K, Colca JR: Glucose transport deficiency in diabetic animals in corrected by treatment with the oral antihyperglycemic agent pioglitazone. Endocrinol 129:1915-1925, 1991
14. Sugiyama Y, Shimura Y, Ikeda H: Effects of pioglitazone on hepatic and peripheral insulin resistance in Wistar fatty rats. Arzneimittelforschung 40:436-440, 1990
15. Tominaga M, Igarashi M, Daimon M, Eguchi H, Matsumoto M, Sekikawa A, Yamatani K, Sasaki H: Thiazolidinediones (AD-4833 and CS-045) improve hepatic insulin resistance in streptozotocin-induced diabetic rats. Endocr J 40:343-349, 1993
16. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR-gamma). J Biol Chem 270:12953-12956, 1995
17. Pagliassoti MJ, Moore MC, Neal DW, Cherrington AD: Insulin is required for the liver to respond to intraportal glucose delivery in the conscious dog. Diabetes 41:1247-1256, 1992
18. Myers SR, McGuinness OP, Neal DW, Cherrington AD: Intraportal glucose delivery alters the relationship between net hepatic glucose uptake and the insulin concentration. J Clin Invest 87:930-939, 1991
19. Hetenyi G Jr, Gauthier C, Byers M, Vranic M: Phlorizin induced normoglycemia partially restores glucoregulation in diabetic dogs. Am J Physiol 256:E277-E283, 1989
20. Adkins BA, Myers SR, Hendrick GK, Stevenson RW, Williams PE, Cherrington AD: Importance of the route of intravenous glucose delivery to hepatic glucose balance in the conscious dog. J Clin Invest 79:557-565, 1987
21. DeFronzo RA, Tobin JD, Andres R: Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237:E214-E223, 1979
22. Leevy CM, Mendenhall CL, Lesko W, Howard MM: Estimation of hepatic blood flow with indocyanine green. J Clin Invest 41:1169-1179, 1962
23. Hartley CJ, Hanley HG, Lewis RM, Cole JS: Synchronized pulsed Doppler blood flow and ultrasonic dimension measurement in conscious dogs. Ultrasound Med Biol 4:99-110, 1978
24. Ho RJ: Radiochemical assay of long-chain fatty acids using 63Ni as tracer. Anal Biochem 36:105-113, 1970
25. Lloyd B, Burrin J, Smythe P, Alberti KGMM: Enzymic fluorometric continuous-flow assays for blood glucose, lactate, pyruvate, alanine, glycerol, and 3-OH-butyrate. Clin Chem 24:1724-1729, 1978
26. Brun C: A rapid method for the determination of para-aminohippuric acid in kidney function tests. J Lab Clin Med 37:955-958, 1951
27. deBodo RC, Steele R, Altszuler N, Dunn A, Bishop JS: On the hormonal regulation of carbohydrate metabolism: studies with 14C glucose. Recent Prog Horm Res 19:445-488, 1963
28. Bradley DC, Steil GM, Bergman RN: Quantitation of measurement error with optimal segments: basis for adaptive time course smoothing. Am J Physiol 264:E902-E911, 1993
29. Dauber L, Greenfield MS, Schulz B, Reaven GM: Enhanced glucose utilization during prolonged glucose clamp studies. Diabetes 30:829-835, 1981
30. Ishida T, Chap Z, Chou J, Lewis R, Hartley C, Entman M, Field JB: Differential effects of oral, peripheral intravenous, and intraportal glucose on hepatic glucose uptake and insulin and glucagon extraction in conscious dogs. J Clin Invest 72:590-600, 1983
31. Caruso G, Proietto J, Calenti A, Alford F: Insulin resistance in alloxan-diabetic dogs: evidence for reversal following insulin therapy. Diabetologia 25:273-279, 1983
32. Finegood DT, Bergman RN, Vranic M: Modeling error and apparent isotope discrimination confound estimation of endogenous glucose production during euglycemic glucose clamps. Diabetes 37:1025-1034, 1988
33. Kawamori R, Kubota MI, Ikeda M, Matsuhisa M, Kubota MA, Morishima T, Kamada T: Acute metabolic effects of exercise on glucose fluxes in splanchnic and peripheral tissues in diabetics determined with an innovative approach. Med Sci Sport Exerc 37:216-226, 1992
34. Parsadanian HK, Ter-Tatevosian LP, Martikian HR, Avakian SH: Changes in the activity of enzymes, participating in glycogen metabolism of alloxan diabetic rats. Mol Cell Biochem 90:185-190, 1989
35. Pugazhenthi S, Khandelwal RL: Kinases and phosphatases of hepatic glycogen metabolism during fasted to refed transition in normal and streptozotocin-induced diabetic rats. Biochem Int. 23:515-524, 1991
36. Pagliassotti MJ, Myers SR, Moore MC, Neal DW, Cherrington AD: Magnitude of negative arterial-portal glucose gradient alters net hepatic glucose balance in conscious dogs. Diabetes 40:1659-1668, 1991
37. Myers SR, Biggers DW, Neal DW, Cherrington AD: Intraportal glucose delivery enhances the effects of hepatic glucose load on net hepatic glucose uptake in vivo. J Clin Invest 88:158-167, 1991
38. Hofmann CA, Edwards CW III, Hillman RM, Colca JR: Treatment of insulin-resistant mice with oral antidiabetic agent pioglitazone: evaluation of liver GLUT2 and phosphoenolpyruvate carboxykinase expression. Endocrinology 130:735-740, 1992
39. Ciaraldi TP, Gilmore A, Olefsky JM, Goldberg M, Heidenreich KA: In vitro studies on the action of CS-045, a new antidiabetic agent. Metabolism 39:1056-1062, 1990
40. Ludvik B, Nolan JJ, Roberts A, Baloga J, Joyce M, Bell JM, Olefsky JM: A noninvasive method to measure splanchnic glucose uptake after oral glucose administration. J Clin Invest 95:2232-2238, 1995
41. Ikeda H, Taketomi S, Sugiyama Y, Shimura Y, Sohda T, Meguro K, Fujita T: Effect of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals. Arzneimittelforschung 40:156-162, 1990